KAREN DOUGLAS: Open Payments
NPI 1295988533 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$762 in 27 payments from 7 companies in 2025. Trend: 2023 $887 · 2024 $650 · 2025 $762
Food & beverage: $762
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $286 |
| Janssen Pharmaceuticals, Inc | 7 | $164 |
| Alkermes, Inc. | 3 | $87 |
| E.R. Squibb & Sons, L.L.C. | 3 | $82 |
| Luye Pharma (USA) Ltd. | 1 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| Axsome Therapeutics, Inc. | 1 | $20 |
Products named: INGREZZA, INVEGA SUSTENNA, COBENFY, ERZOFRI EXTENDED-RELEASE, ARISTADA, CAPLYTA, LYBALVI, Auvelity.
Industry payments across MI — which companies pay providers there.
